0.53

0.95% 0.005

Cero Therapeutics Holdings Inc (CERO)

Overview News Price History Discussions Forecast

Cero Therapeutics Holdings Inc stock is traded at $0.53, with a volume of 246.55K. It is up +0.95% in the last 24 hours and down -33.70% over the past month. CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Previous Close:

$0.525

Open:

$0.5171

24h Volume:

246.55K

Relative Volume:

0.14

Market Cap:

$4.09M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-9.40%

1M Performance:

-33.70%

6M Performance:

-97.57%

1Y Performance:

-99.44%

1-Day Range:

$0.5158

$0.535

1-Week Range:

$0.4901

$0.62

52-Week Range:

$0.4901

$109.00

Cero Therapeutics Holdings Inc Stock (CERO) Company Profile

Name

Cero Therapeutics Holdings Inc

Sector

Healthcare (1173)

Industry

Biotechnology (666)

Phone

650-407-2376

Address

201 HASKINS WAY, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CERO's Discussions on Twitter

Compare CERO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CERO Cero Therapeutics Holdings Inc	0.53	3.26M	0	0	0	0.00
ONC Beigene Ltd Adr	241.43	27.03B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	436.00	112.64B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.335	40.86M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	588.34	64.17B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	75.06	6.07B	0	-153.72M	-103.81M	-2.00

Cero Therapeutics Holdings Inc Stock (CERO) Latest News

May 20, 2025

CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at Maxim Group - Defense World

May 20, 2025

May 19, 2025

Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq

May 19, 2025

Maxim Group sets Cero Therapeutics stock with $3 target By Investing.com - Investing.com Nigeria

May 19, 2025

CERO Therapeutics (CERO) Receives 'Buy' Rating from Maxim Group | CERO Stock News - GuruFocus

May 19, 2025

Maxim Group sets Cero Therapeutics stock with $3 target - Investing.com

May 19, 2025

CeroTherapeutics (CERO) Receives Buy Rating from Maxim Analyst | CERO Stock News - GuruFocus

May 19, 2025

Cero Therapeutics (CERO) Gains Buy Rating with Innovative T-Cell Therapy | CERO Stock News - GuruFocus

May 19, 2025

May 16, 2025

CERo Therapeutics (NASDAQ:CERO) Stock Price Up 1.5% – Here’s What Happened - Defense World

May 16, 2025

May 15, 2025

CERo Therapeutics regains Nasdaq compliance, eyes trials - Investing.com Australia

May 08, 2025

CERo Therapeutics regains Nasdaq compliance, eyes trials By Investing.com - Investing.com South Africa

May 08, 2025

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) - The Manila Times

May 08, 2025

CERo Therapeutics Regains Compliance with Nasdaq Listing Rule Following Successful Fundraising Efforts - Nasdaq

May 08, 2025

May 03, 2025

CERo Therapeutics Holdings Inc (NASDAQ: CERO): Blank Check On Growth? - Stocksregister

May 03, 2025

May 02, 2025

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity - ADVFN

May 02, 2025

Apr 30, 2025

CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com Australia

Apr 30, 2025

CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia - Nasdaq

Apr 30, 2025

Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia - marketscreener.com

Apr 30, 2025

CERo Therapeutics Holdings, Inc. Announces TriStar - GlobeNewswire

Apr 30, 2025

Leading Cancer Center to Test Revolutionary AML Treatment: CERo's Novel T Cell Therapy Enters Clinical Trial - Stock Titan

Apr 30, 2025

Apr 28, 2025